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ABSTRACT 
Forced degradation studies of new drug substances and drug product are important to help develop and demonstrate specificity of 
stability indicating methods and provide knowledge about possible degradation pathways and degradation products of the active 
ingredients and help elucidate the structure of the degradants. They were also useful in the investigation of chemical and physical 
stability of crystal forms. It is better to start degradation studies earlier in the drug development process to have sufficient time to 
gain more information about the stability of the molecule. This information will in turn help improve the formulation manufacturing 
process and determine the storage conditions. As no specific set of conditions is applicable to all drug products and drug substances 
and the regulatory guidance does not specify the conditions to be used, this study requires the experimenter to use common sense. 
The aim of any strategy used for forced degradation is to produce the desired amount of degradation i.e., 5–20%. Adequate 
degradation required to understand the probable degradants for the evaluation of stability indicating method. It has become 
mandatory to perform stability studies of new drug moiety before filing in registration dossier. The stability studies include long 
term studies (12 months) and accelerated stability studies (6 months).  
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INTRODUCTION 
Forced degradation studies are also known as stress 
testing, stress studies, stress decomposition studies, 
forced decomposition studies, etc. Forced degradation is 
a process that involves degradation of drug products and 
drug substances at conditions more severe than 
accelerated conditions and thus generates degradation 
products that can be studied to determine the stability of 
the molecule. The ICH guideline states that stress testing 
is intended to identify the likely degradation products 
which further helps in determination of the intrinsic 
stability of the molecule and establishing degradation 
pathways, and to validate the stability indicating 
procedures used 
1, 2
. But these guidelines are very 
general in conduct of forced degradation and do not 
provide details about the practical approach towards 
stress testing. Although forced Degradation studies area 
regulatory requirement and scientific necessity during 
drug development, it is not considered as a requirement 
for formal stability program. The FDA and ICH 
guidance’s state the requirement of stability testing data 
to understand how the quality of a drug substance and 
drug product changes with time under the influence of 
various environmental factors. Knowledge of the 
stability of molecule helps in selecting proper 
formulation and package as well as providing proper 
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storage conditions and shelf life, which is essential for 
regulatory documentation
3, 4
. 
REGULATORY GUIDELINES 
Various International guidelines recommended forced 
degradation studies ICH guidelines sometimes apply 
only to the marketing applications for new products and 
do not cover the part during clinical development. The 
ICH guidelines that are applicable to forced degradation 
studies are 
5-7
. 
The ICH guidelines that are applicable to forced 
degradation studies are 
ICH Q1A Stability Testing of New Drug Substances and 
Products 
ICH Q1B Photo stability Testing of New Drug 
Substances and Products 
ICH Q2B Validation of Analytical Procedures: 
Methodology 
ICH Q1A (Stress testing): 
Recommended conditions for performing forced 
degradation studies on drug substances and drug 
products. The recommendations are to inspect the 
results of temperature (above that for accelerated testing, 
i.e., >50 C), humidity (75% relative humidity), 
oxidation and photolysis. Wide pH range should be 
considered in the testing of solution or suspension. 
Ultimately the stability-indicating method developed by 
these samples 
8, 9
. 
ICH Q1B:  
Recommended approaches to assessing the photo 
stability of drug substances and drug products. For drug 
substance and drug product forced degradation 
conditions are specified in  
Section II and Section III respectively. Forced 
degradation studies exposure levels are not defined. 
Solid or in solution/suspension, photo stability testing 
can be performed. These samples are then used to 
develop a stability indicating method. Some of the 
degradation products formed during forced degradation 
studies may not really be experiential to form during 
stability studies in which case they need not be 
examined further 
10-11
.  
ICH Q2B:  
Gives guidance to validate the analytical methodology. 
To prove specificity, in section B 1.2.2 (impurities not 
available) there is a suggestion to utilize samples from 
forced degradation   studies. Whether the analytical 
method is stability indicating or not ‘specificity’ is a key 
factor. 
ICH Q3A (R2):  
With respect to both chemistry and safety prospects the 
identification of each impurity is required. The chemical 
prospects include classification and identification of 
impurities, report creation, catalogue of impurities in the 
specification and a concise discussion of analytical 
methods. The safety prospects include specific guidance 
for qualifying those impurities that were not present or 
were present at significantly minor levels in batch of a 
new drug substance 
12-13
. 
Impartial of forced degradation studies 
Forced degradation studies are carried out to achieve the 
following purposes: 
 To establish degradation pathways of drug 
substances and drug products. 
 To differentiate degradation products that is related 
to drug products from those that are     generated 
from non-drug product in a formulation. 
 To determine the intrinsic stability of a drug 
substance in formulation. 
 To reveal the degradation mechanisms such as 
hydrolysis, oxidation, thermolysis or photolysis of 
the drug substance and drug product. 
 To produce a degradation profile similar to that of 
what would be observed in a formal stability study 
under ICH conditions. 
 To distinguish degradation products that is related 
to drug products from those that are generated from 
non-drug product in a formulation.  
 To generate stability indicating nature of a 
developed method. 
 To produce more stable formulations. It also helps 
in determining the expiry date of a particular 
formulation. 
Time to accomplish forced degradation 
It is very important to know when to perform forced 
degradation studies for the development of new drug 
substance and new drug product. FDA guidance states 
that stress testing should be performed in phase III of 
regulatory submission process. Stress studies should be 
done in different pH solutions, in the presence of 
oxygen and light, and at elevated temperatures and 
humidity levels to determine the stability of the drug 
substance. These stress studies are conducted on a single 
batch. The results should be summarized and submitted 
in an annual report. However, starting stress testing 
early in preclinical phase or phase I of clinical trials is 
highly encouraged and should be conducted on drug 
substance to obtain sufficient time for identifying 
degradation products and structure elucidation as well as 
optimizing the stress conditions. An early stress study 
also gives timely recommendations for making 
improvements in the manufacturing process and proper 
selection of stability-indicating analytical procedures 
14-
15
. 
Limits for degradation 
Forced degradation is important part of the drug 
development process as it provides knowledge about the 
degradation chemistry of drug substances and drug 
products. This knowledge is used primarily to develop 
stability- indicating analytical methods but also useful 
for other purposes such as formulation development, 
packaging development and the design of the official 
stability studies. As there is no formal regulatory 
guidance for forced degradation, it is recommended to 
use appropriate conditions to achieve 5-20% 
degradation.  
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Degradation studies of a drug substance  
FDA demands the following at the time of registration. 
 Stressing the drug substance in solution or 
suspension at alkaline and acidic pH and under 
oxidation conditions. 
 Stressing the solid bulk drug substance at 
temperature and temperature + humidity conditions 
in excess of accelerated conditions. 
 Stressing the drug substance photolytically in the 
solid state or in solution excess. 
 Demonstration of the specificity of stability 
indicating methods with forced degraded samples. 
 Full characterization of the degraded products by 
means of NMR, mass spectrometry (MS), UV 
analysis 
 Chemical and physical properties of the degradation 
products, if available. 
 The mechanism and kinetics of degradation 
products formed, if available 
16, 17
. 
Strategy for selection of degradation conditions 
Forced degradation is carried out to produce 
representative samples for developing stability-
indicating methods for drug substances and drug 
products. The choice of stress conditions should be 
consistent with the product's decomposition under 
normal manufacturing, storage, and use conditions 
which are specific in each case. A general protocol of 
degradation conditions used for drug substance and drug 
product is shown in figure no.1. 
 
 
Figure 1: An illustrative flowchart describing various stress conditions used for degradation of drug substance 
and drug product. 
Strategic development of Forced Degradation: 
The structural multiplicity of drug molecules makes it 
difficult to develop the generic set of conditions for a 
forced degradation study. The selected stress conditions 
should be reliable with the product’s decomposition 18, 
19
. The selected condition should include products 
property and its degradation under normal 
manufacturing, storage and use conditions. General 
protocol Figure 2 illustrates the approach for forced 
degradation. Forced degradation factors necessary 
include acid and base hydrolysis, thermal degradation, 
photolysis, and oxidation and may include freeze–thaw 
cycles and shear 
20, 21
.  
 
 
Figure 2: Approach for force degradation 
Stability indicating method develop by other 
analytical technique 
Stability-indicating methods will be characterized by 
potency, purity and biological activity. The selection of 
tests is product specific. Stability indicating methods 
may include various methods like electrophoresis (SDS-
PAGE, immunoelectrophoresis, Western blot, high-
resolution chromatography (e.g., reversed phase 
chromatography, SEC, gel filtration, ion exchange, and 
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affinity chromatography) and peptide mapping. The 
analytical method of choice should be sensitive enough 
to detect impurities at low levels (i.e., 0.05% of the 
analyte of interest or lower) and the peak responses 
should fall within the range of detector's linearity. The 
analytical method should be capable of capturing all the 
impurities formed during a formal stability study at or 
below ICH threshold limits. Degradation product 
identification and characterization are to be performed 
based on formal stability results in accordance with ICH 
requirements. Conventional methods (e.g., column 
chromatography) or hyphenated techniques (e.g., LC–
MS, LC–nuclear magnetic resonance (NMR)) can be 
used in the identification and characterization of the 
degradation products. Use of these techniques can 
provide a better insight into the structure of the 
impurities that could add to the knowledge space of 
potential structural alerts for genotoxicity and the 
control of such impurities with tighter limits. It should 
be noted that structural characterization of degradation 
products is necessary for those impurities formed during 
formal shelf-life stability studies and above the 
qualification threshold limit 
22, 23
. By suitable LC-MS 
conditions, the mass numbers of impurities/ degradants 
get confirm and further identify the mass of major 
degradants which are found to be forming greater than 
1.0% during stress studies. LCMS help to illustrate the 
structures of the major degradants. Similar molecular 
weights compound may exhibit similar UV profiles, in 
such cases; attempts must be made to modify the 
chromatographic parameters to achieve necessary 
separation. To detect and quantitation of all the potential 
impurities and degradants an optimal wavelength should 
be used. The developed method should be validated as 
per the ICH guidelines 
24, 25
. 
DEGRADATION CONDITIONS 
Hydrolytic conditions 
Over a wide range of pH most common degradation, 
chemical reactions are Hydrolysis The decomposition of 
a chemical compound by reaction with water is called 
Hydrolysis. In acidic and basic hydrolysis the catalysis 
of ionisable functional groups present in the molecule 
occurs. Forced degradation of a drug substance occurs 
when the drug interacts with acid and base. It produces 
primary degradants in the desirable range. Depending on 
the stability of the drug substance the class and 
concentrations of acid or base taken should be decided. 
For acid hydrolysis hydrochloric acid or sulphuric acids 
(0.1-1 M) considered to be most suitable whereas 
sodium hydroxide or potassium hydroxides (0.1-1M) for 
base hydrolysis are suggested. Co-solvents can be used 
if compounds are poorly soluble in water. Forced 
degradation started at room temperature and further 
temperature increased if there is no degradation 
26, 27
. 
Oxidation conditions 
Hydrogen peroxide is widely used for oxidation of drug 
substances in forced degradation studies but other 
oxidizing agents such as metal ions, oxygen, and radical 
initiators (e.g., azobisisobutyronitrile, AIBN) can also 
be used. Selection of an oxidizing agent, its 
concentration, and conditions depends on the drug 
substance. It is reported that subjecting the solutions to 
0.1–3% hydrogen peroxide at neutral pH and room 
temperature for seven days or up to a maximum 20% 
degradation could potentially generate relevant 
degradation products. The oxidative degradation of drug 
substance involves an electron transfer mechanism to 
form reactive anions and cations. Amines, sulfides and 
phenols are susceptible to electron transfer oxidation to 
give N-oxides, hydroxylamine, sulfones and sulfoxide. 
The functional group with labile hydrogen like benzylic 
carbon, allylic carbon, and tertiary carbon or α-positions 
with respect to hetro atom is susceptible to oxidation to 
form hydro peroxides, hydroxide or ketone 
28-30
. 
Photolytic conditions 
The photo stability testing of drug substances must be 
evaluated to demonstrate that a light exposure does not 
result in unacceptable change. Photo stability studies are 
performed to generate primary degradants of drug 
substance by exposure to UV or fluorescent conditions. 
Some recommended conditions for photostability testing 
are described in ICH guidelines 
31
. Samples of drug 
substance and solid/liquid drug product should be 
exposed to a minimum of 1.2 million lx h and 
200 W h/m
2
 light. The most commonly accepted 
wavelength of light is in the range of 300–800 nm to 
cause the photolytic degradation. The maximum 
illumination recommended is 6 million lx h. Light stress 
conditions can induce photo oxidation by free radical 
mechanism. Functional groups like carbonyls, nitro 
aromatic, N-oxide, alkenes, aryl chlorides, weak C-H 
and O-H bonds, sulfides and polyenes are likely to 
introduce drug photosensitivity 
32, 33
. 
Thermal conditions 
Thermal degradation (e.g., dry heat and wet heat) should 
be carried out at more strenuous conditions than 
recommended ICH Q1A accelerated testing conditions. 
Samples of solid-state drug substances and drug 
products should be exposed to dry and wet heat, while 
liquid drug products should be exposed to dry heat. 
Studies may be conducted at higher temperatures for a 
shorter period. Effect of temperature on thermal 
degradation of a substance is studied through the 
Arrhenius equation: 
K= Ae - Ea/RT 
where k is specific reaction rate, A is frequency factor, 
Ea is energy of activation, R is gas constant 
(1.987 cal/deg mole) and T is absolute temperature. 
Thermal degradation study is carried out at 40–80 °C. 
Humidity conditions 
Humidity is one of the effective factors in establishing 
the potential degradants in the finished product and 
active pharmaceutical ingredient. Normally 90% 
humidity for the duration of one week shall be 
recommended for the establishment of forced 
degradation samples 
34
. 
Stability Indicating Method 
A stability indicating method (SIM) is an analytical 
procedure used to quantitate the decrease in the amount 
of the active pharmaceutical ingredient (API) in drug 
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product due to degradation. According to an FDA 
guidance document, a stability-indicating method is a 
validated quantitative analytical procedure that can be 
used to detect how the stability of the drug substances 
and drug products changes with time 
35
. A stability-
indicating method accurately measures the changes in 
active ingredients concentration without interference 
from other degradation products, impurities and 
excipients. Stress testing is carried out to demonstrate 
specificity of the developed method to measure the 
changes in concentration of drug substance when little 
information is available about potential degradation 
product. The development of a suitable stability 
indicating method provides a background for the pre-
formulation studies, stability studies and the 
development of proper storage requirements. The RP-
HPLC is a most widely used analytical tool for 
separation and quantifying the impurities and it is most 
frequently coupled with a UV detector. The following 
are the steps involved for development of SIM on HPLC 
which meets the regulatory requirements 
36, 37
. 
Sample generation 
For generating samples for SIM the API is force 
degraded at conditions more severe than accelerated 
degradation conditions. It involves degradation of drug 
at hydrolytic, oxidative, photolytic and thermal 
conditions as discussed earlier. The forced degradation 
of API in solid state and solution form is carried out 
with an aim to generate degradation products which are 
likely to be formed in realistic storage conditions. This 
sample is then used to develop an SIM 
38
. 
Method development and optimization 
Before starting the method development, various 
physiochemical properties like pKa value, log P, 
solubility and absorption maximum of the drug must be 
known, for it lays a foundation for HPLC method 
development. Log P and solubility helps select mobile 
phase and sample solvent while pKa value helps 
determine the pH of the mobile phase. Reverse phase 
column is a preferred choice to start the separation of 
sample components as the degradation is carried out in 
aqueous solution. Methanol, water and acetonitrile can 
be used as mobile phase in various ratios for the initial 
stages of separation. Selection between methanol and 
acetonitrile for organic phase is based on the solubility 
of the analyte. Initially the water: organic phase ratio 
can be kept at 50:50 and suitable modifications can be 
made as trials proceed to obtain a good separation of 
peaks. Latter buffer can be added if it is required to 
obtain better peak separation and peak symmetry. If the 
method is to be extended to liquid chromatography–
mass spectrometry (LC–MS), then mobile phase buffer 
should be MS compatible like triflouroacetic acid and 
ammonium formate. Variation in column temperature 
affects the selectivity of the method as analytes respond 
differently to temperature changes. A temperature in the 
range of 30–40 °C is suitable to obtain good 
reproducibility. It is better to push the drug peak further 
in chromatogram as it results in separation of all 
degradation products. Also a sufficient run time after the 
drug peak is to be allowed to obtain the degradants peak 
eluting after the drug peak 
39-41
. 
SUMMARY AND CONCLUSION 
Forced degradation studies are indispensable in the 
development of stability-indicating and degradant -
monitoring methods as part of a validation protocol. 
Forced degradation studies also provide invaluable 
insight in investigating degradation products and 
pathways of drug substances and products. Even though 
the ICH and FDA guidance documents only call for the 
inclusion of these studies in Phase III of the regulatory 
submission process, it is strongly recommended these 
studies be started as early as possible to be able to 
provide valuable information that can be used to assess 
the inherent stability of a drug, and to improve 
formulations and the manufacturing process. Given that 
no specific set of conditions will be applicable to all 
drug substances and products, the pharmaceutical 
scientist should ensure the stress conditions are 
consistent with product decomposition under normal 
manufacturing, storage, and intended use conditions. 
Recommended stress factors include high and low pH, 
elevated temperature, photolysis, and oxidation. Care 
should be taken to avoid under-stressing or unduly over-
stressing the drug substance or product, for this may 
lead to aberrant and non-representative results. A 
degradation level of approximately 10% of the drug 
substance should be optimal for method optimization. 
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